EGRX - Eagle Pharmaceuticals, Inc. -  [ ]

Ticker Details
Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.
IPO Date: February 12, 2014
Sector: Healthcare
Industry: Drug Manufacturers
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.97 | 8.45%
Avg Daily Range (30 D): $0.06 | 22.62%
Avg Daily Range (90 D): $0.11 | 60.19%
Institutional Daily Volume
Avg Daily Volume: .17M
Avg Daily Volume (30 D): M
Avg Daily Volume (90 D): M
Trade Size
Avg Trade Size (Sh.): 81
Avg Trade Size (Sh.) (30 D): 387
Avg Trade Size (Sh.) (90 D): 1,113
Institutional Trades
Total Institutional Trades: 2,324
Avg Institutional Trade: $1.52M
Avg Institutional Trade (30 D): $1M
Avg Institutional Trade (90 D): $1M
Avg Institutional Trade Volume: .03M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.5M
Avg Closing Trade (30 D): $.76M
Avg Closing Trade (90 D): $.76M
Avg Closing Volume: 31.5K
 
News
Apr 9, 2026 @ 9:38 PM
Did Eagle Pharmaceuticals, Inc. Insiders Breach th...
Source: Halper Sadeh Llc
Dec 24, 2025 @ 5:30 PM
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS,...
Source: Prnewswire
Oct 6, 2025 @ 11:30 PM
Eagle Pharmaceuticals Announces Availability of Un...
Source: Na
Aug 28, 2025 @ 11:30 PM
Eagle Pharmaceuticals to Appoint Abhinav Jain to i...
Source: Na
Oct 14, 2024 @ 10:13 PM
Snowflake, Eagle Pharmaceuticals, Blue Ridge Banks...
Source: Johnson Fistel, Llp
Financials
  TTM Q2 2023 Q1 2023
Basic EPS $.92 $.39 $.44
Diluted EPS $.91 $.39 $.44
Revenue $257.55M $64.65M $66.31M
Gross Profit $184.28M $47.79M $49.01M
Net Income / Loss $11.95M $5.16M $5.75M
Operating Income / Loss $41.01M $10.3M $11.77M
Cost of Revenue $73.27M $16.86M $17.3M
Net Cash Flow $-21.21M $-6.54M $-33.42M
PE Ratio